merck — Lorien Times

New mRNA vaccine could reduce the recurrence and spread of skin cancer

The market’s reaction to Moderna and Merck's personalized mRNA vaccine for melanoma—a spectacular 177% surge in Moderna’s stock, according to CNBC—is pure adrenaline.

By Dana Whitfield · August 20, 2026

Moderna/Merck stock frenzy ignores universal rights for mRNA therapy

The sheer velocity of the stock market is always the most exhausting part of any major announcement.

By Aoife Gallagher · August 20, 2026

Moderna's 130% gain must prove US manufacturing for Medicare access

I’ve spent my life scoring things in payroll. I track whether a promise lands on a spreadsheet: who gets hired, at what wage, and if the work remains there five years from now.

By Ray Dombrowski · August 19, 2026